Adicet Bio, Inc.

Consolidated net sales were $164.4 million, down 11.3% from $185.3 million a year ago. Gross profit was $25.5 million versus $40.0 million, and gross margin was 15.5% versus 21.6%. The company reported a net loss of $21.1 million, or $0.59 per share, versus net income of $0.5 million, or $0.01 per share, in the prior-year quarter. Human Health sales were $80.8 million, down 23.7%, with gross profit of $8.5 million and gross margin of 10.5%; Pharmaceutical Ingredients sales were $38.8 million, up 6.2%, with gross profit up 18.1% to $6.9 million and gross margin of 17.7%; Performance Chemicals sales were $44.7 million, up 4.8%, with gross profit up 6.5% to $10.1 million and gross margin of 22.6%. Management said fiscal 2019 still calls for 15 to 20 generic launches and just under $8 million in R&D milestone payments. It also said first-half tariff impact is expected to be $70,000 to $90,000, and if tariffs rise to 25% on January 1, the second-half impact could be $850,000 to $3.7 million.

Bill Kennally framed the quarter as a mixed start: the company’s non-generic businesses are steady cash contributors, while Rising is still working through generic-industry headwinds. He emphasized that supply-chain fixes are now taking hold, saying failure-to-supply claims have fallen for the third consecutive quarter and back orders are down to under 4% of SKUs. He also said the Rising pipeline has been reorganized, with parked products being reactivated where possible, and described the business as being “poised and ready to return to growth.”

Becky Roof focused on the financial pressure from Rising, SG&A tied to the strategic review, and the balance sheet. She noted $6.5 million of failure-to-supply claims in the quarter, with $3 million re-billed to partners, and said Rising could potentially reverse up to $13.3 million of claims depending on negotiations. Cash, cash equivalents and short-term investments were $52.5 million at September 30, debt was $315.4 million, and cash used in operating activities was $46.4 million; she also said the company repaid $3.8 million in bank loans. She explained that inventory rose to $156.5 million because of Rising safety stock, API build ahead of later-quarter shipments, and Performance Chemicals inventory built ahead of potential tariff increases. Management said the strategic alternatives process is intended to retire debt and believes cash, liquid assets and operating cash flow, plus liquidity from that process, will fund working capital needs for the next 12 months.

Analysts pressed management on liquidity, the bank covenant, and whether the strategic alternatives process implies distress. Roof said the covenant is a liquidity test, not a pure cash covenant, and that the recent bank waiver was a sign of support; she also said management is not concerned about delisting at this point. Questions on Rising focused on failure-to-supply trends and pricing pressure; Kennally said volumes are up but pricing is down, with one large product hit by a competitor, and he said price declines are beginning to soften. Analysts also asked about the VA appeal and the Rising pipeline: Kennally said the government appealed the favorable ruling, but the company is rebuilding business with the VA and expects the lower court decision to be affirmed; he said recent ANDA approvals are “singles” and that new launches should begin contributing soon, though timing is uncertain.